

Table of Contents

Sect. I	History and Epidemiology	1
1	History of Ductal Carcinoma in Situ	3
2	Why Study Ductal Carcinoma in Situ	12
3	The Natural History of Ductal Carcinoma in Situ of the Breast	17
4	The Epidemiology of Breast Carcinoma in Situ	22
Sect. II	Carcinogenesis and Biology	35
5	Biologic Characteristics of Ductal Carcinoma in Situ	37
6	Prognostic Factors in Ductal Carcinoma in Situ	49
7	HER-2/neu Gene Amplification and Overexpression in Ductal Carcinoma in Situ	54
8	New Insights into the Pathogenesis of in Situ Carcinomas of the Breast by Means of Comparative Genomic Hybridization (CGH)	67
9	Model Systems for Ductal Carcinoma in Situ	77
Sect. III	Detection and Evaluation	85
10	Mammographic Appearances of in Situ Carcinomas	87
11	Ductal Carcinoma in Situ: A Radiological Perspective	105
12	Roles of Breast Magnetic Resonance Imaging for Ductal Carcinoma in Situ	118
13	Ultrasound of Ductal Carcinoma in Situ	128
Sect. IV	Biopsy Techniques	171
14	Minimally Invasive Biopsy	173
15	Breast Biopsy and Oncoplastic Surgery for the Patient with Ductal Carcinoma in Situ: Surgical, Pathologic, and Radiologic Issues	185
Sect. V	Pathology	205
16	Practical Pathology of Duct Carcinoma in Situ: How to Derive Optimal Data from the Pathologic Examination	207
17	The Van Nuys Ductal Carcinoma in Situ Classification: An Update	222
18	Angiogenesis in Ductal Carcinoma in Situ of the Breast	234
19	The Local Distribution of Ductal Carcinoma in Situ of the Breast: Whole-Organ Studies	240
20	Large-Section (Macrosection) Histologic Slides	249
21	Predicting Local Recurrence in Patients with Ductal Carcinoma in Situ	255
22	The Diagnostic Reproducibility of Ductal Carcinoma in Situ	264
Sect. VI	Treatment of Ductal Carcinoma in Situ	273
23	Surgical Overview of the Treatment of Ductal Carcinoma in Situ	275
24	Overview of Conservative Surgery and Radiation Therapy Ductal Carcinoma in Situ	287
25	The Lagios Experience	303
26	Treatment of Subclinical Ductal Carcinoma in Situ of	308

	the Breast by Local Excision and Surveillance: An Updated Personal Experience	
27	Ductal Carcinoma in Situ: Experience at Nottingham City Hospital 1973 through 2000	322
28	Ductal Carcinoma in Situ: The Memorial Sloan-Kettering Cancer Center Experience	329
29	The Van Nuys/USC Experience by Treatment	337
30	Ductal Carcinoma in Situ: The Edinburgh Experience	343
31	The Florence Experience	348
32	Bayreuth-Erlangen Experience of "Risk-Adapted" Therapy of Ductal Carcinoma in Situ	354
33	An International Collaborative Study: A 15-Year Experience	359
34	Breast-Conserving Surgery Plus Radiation Therapy in Ductal Carcinoma in Situ: The Institut Curie Experience	367
35	Joint Center for Radiation Therapy Experience	373
36	The Impact of Young Age on Outcome in Patients with Ductal Carcinoma in Situ: The William Beaumont Hospital Experience	381
37	Breast Conserving Therapy for Ductal Carcinoma in Situ: The Van Nuys Experience with Excision Plus Radiation Therapy	394
38	Ductal Carcinoma in Situ: Collected Experience of the French Regional Comprehensive Cancer Centers	400
39	Should All Ductal Carcinoma in Situ Patients Receive Radiation Therapy and Is Partial Breast Irradiation an Option?	407
40	Randomized Trial Overview	414
41	Prospective Clinical Trials: The National Surgical Adjuvant Breast Project Experience	420
42	Prevention of Invasive Breast Cancer in Women with Ductal Carcinoma in Situ: An Update of the National Surgical Adjuvant Breast and Bowel Project Experience	432
43	An Update on European Organization for Research and Treatment of Cancer Trial 10853 for Ductal Carcinoma in Situ of the Breast	447
44	Radiotherapy and Tamoxifen after Complete Excision of Ductal Carcinoma in Situ of the Breast	453
Sect. VII	Tools for Selecting Patients for Breast Conservation with and without Radiation Therapy	457
45	The University of Southern California/Van Nuys Prognostic Index	459
46	Problems with the Use of the Van Nuys Prognostic Index	474
47	Margin Width as the Sole Predictor of Local Recurrence in Patients with Ductal Carcinoma in Situ of the Breast	482
Sect. VIII	Adjuvant Therapy, Prevention, and Hormone	495

	Replacement Therapy	
48	Can the New Prevention Strategies Reduce the Incidence of Ductal Carcinoma in Situ?	497
49	Tamoxifen and/or Hormone Replacement Therapy after Treatment of Ductal Carcinoma in Situ	502
50	Tamoxifen Chemoprevention for Ductal Carcinoma in Situ: Magic Bullet or Misstep?	508
Sect. IX	Other Issues	513
51	Mastectomy and Immediate Reconstruction for Extensive Ductal Carcinoma in Situ of the Breast	515
52	Ductal Carcinoma in Situ with Microinvasion	523
53	Management of the Contralateral Breast	530
54	Extensive Intraductal Component in Association with Invasive Breast Cancers	536
55	Salvage of Local-Regional Failure	539
56	Outcome after Invasive Local Recurrence in Patients with Ductal Carcinoma in Situ of the Breast	545
57	Axillary Dissection for Ductal Carcinoma in Situ	554
58	The Role of Sentinel Lymph Node Biopsy in Ductal Carcinoma in Situ: The Memorial Sloan-Kettering Opinion	565
59	Explaining Ductal Carcinoma in Situ to Patients: The Role of Specific Information and Absolute Risks	571
60	Ductal Carcinoma in Situ of the Male Breast	577
61	Interstitial Therapy of Ductal Carcinoma in Situ: Where Does It Stand?	581
Sect. X	The Ductal Carcinoma in Situ Consensus Conferences	585
62	The European Organization for Research and Treatment of Cancer Ductal Carcinoma in Situ Consensus Meetings	587
63	The Classification and Treatment of Ductal Carcinoma in Situ of the Breast: Summary of the 1997 and 1999 Consensus Conferences	594
Sect. XI	Other Noninvasive Breast Cancers and Preneoplastic Diseases	601
64	Breast-Conserving Treatment of Paget's Disease of the Breast with Radiotherapy	603
65	Paget's Disease	607
66	Lobular Carcinoma in Situ	615
67	Pathology of Ductal Carcinoma in Situ: Proliferative and Nonproliferative Benign Breast Disease	635
Sect. XII	Conclusion	641
68	Editors' Consensus	643
	Index	651